Table 2

Comparison of clinicopathological features between patients with villoglandular adenocarcinoma and those with standard cervical adenocarcinoma*

Villoglandular adenocarcinoma (n=47)Standard adenocarcinoma (n=104)P value
Median age±SD43.8±7.647.1±8.90.029*
BMI, kg/m2 22.2±2.923.0±2.80.22
Menopause33104<0.001*
 Yes27/33 (81.8)69 (66.3)
 No6/33 (18.2)35 (33.7)
FIGO stage (2009)0.001*
 IA1013 (12.5)
 IA24 (8.5)5 (4.8)
 IB135 (74.5)83 (79.8)
 IB28 (17.0)3 (2.9)
Surgery0.79
 Radical hysterectomy42 (89.4)90 (86.5)
 Simple hysterectomy5 (10.6)14 (13.5)
Adjuvant therapy
 Yes28 (59.6)64 (61.5)0.86
 No19 (40.4)40 (38.5)
Grade0.003*
 Ⅰ13/28 (46.4)10/57 (17.5)
 Ⅱ14/28 (50.0)28 (49.1)
 Ⅲ1/28 (3.6)19 (33.3)
Tumor size (mean±SD)3.0±1.32.6±1.30.20
 <2 cm14 (29.8)49/101 (48.5)
 2–4 cm21 (44.7)41/106 (40.6)
 ≥4 cm12 (25.5)11/106 (10.9)
Depth of cervical interstitial infiltration0.004*
 ≤1/228/40 (70.0)40/60 (66.7)
 >1/212/40 (30.0)20/60 (33.3)
Lymphovascular invasion0.37
 Yes2/36 (5.6)11/75 (14.7)
 No34/36 (94.4)64/75 (85.3)
Uterine infiltration0.32
 Yes3 (6.4)5 (4.8)
 No44 (93.6)99 (95.2)
Parametrium invasion1.00
 Yes01 (1.0)
 No47 (100.0)103 (99.0)
Lymph node metastasis0.72
 Yes2/40 (5.0)8/90 (8.9)
 No38/40 (95.0)82/90 (91.1)
Recurrence06
Median relapse-free survival
±SD (months)
60.5±36.033.4±25.4<0.001*
Death03
Median survival time ±SD (months)60.5±36.034.5±25.6<0.001*
  • *Results are number (%) unless stated otherwise

  • BMI, body mass index; SD, standard deviation.